Appointment of Nominated Adviser and Broker

RNS Number : 1804U
Scancell Holdings Plc
14 October 2014
 



14 October 2014

 

Scancell Holdings Plc

('Scancell')

 

Appointment of Nominated Adviser and Broker

 

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer has appointed Panmure Gordon (UK) Limited as its Nominated Adviser and Broker with immediate effect.

 

-ENDS-

 

For Further Information:

 

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 20 3727 1000




Robert  Naylor/Freddy Crossley/
Maisie Atkinson

Panmure Gordon (UK) Limited

+ 44 (0) 20 7886 2500




Mo Noonan/Simon Conway

FTI Consulting

+ 44 (0) 20 3727 1000

 

About Scancell

 

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.  

 

Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial.  Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

 

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

 

Pre-clinical data on a combination of SCIB1 and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway), has shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity.  The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPBLBDGDUBBGSX
UK 100

Latest directors dealings